144 related articles for article (PubMed ID: 34381563)
1. High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer.
Ferreira JM; Matheus LHG; de Almeida RVS; Melo PAS; Leite KRM; Murta CB; Claro JFA; Camacho CP; Pontes-Júnior J; Dellê H
Oncotarget; 2021 Aug; 12(16):1580-1586. PubMed ID: 34381563
[TBL] [Abstract][Full Text] [Related]
2. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
[TBL] [Abstract][Full Text] [Related]
3. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.
Montalbán Del Barrio I; Penski C; Schlahsa L; Stein RG; Diessner J; Wöckel A; Dietl J; Lutz MB; Mittelbronn M; Wischhusen J; Häusler SFM
J Immunother Cancer; 2016; 4():49. PubMed ID: 27532024
[TBL] [Abstract][Full Text] [Related]
4. CD39 and CD73 in the aortic valve-biochemical and immunohistochemical analysis in valve cell populations and its changes in valve mineralization.
Kaniewska-Bednarczuk E; Kutryb-Zajac B; Sarathchandra P; Pelikant-Malecka I; Sielicka A; Piotrowska I; Slominska EM; Chester AH; Yacoub MH; Smolenski RT
Cardiovasc Pathol; 2018; 36():53-63. PubMed ID: 30056298
[TBL] [Abstract][Full Text] [Related]
5. Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer.
Gardani CFF; Pedrazza EL; Paz VS; Zanirati GG; da Costa JC; Andrejew R; Ulrich H; Scholl JN; Figueiró F; Rockenbach L; Morrone FB
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004484
[TBL] [Abstract][Full Text] [Related]
6. Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction.
Knight JS; Mazza LF; Yalavarthi S; Sule G; Ali RA; Hodgin JB; Kanthi Y; Pinsky DJ
Front Immunol; 2018; 9():1322. PubMed ID: 29942314
[TBL] [Abstract][Full Text] [Related]
7. Targeting the purinergic pathway in breast cancer and its therapeutic applications.
de Araújo JB; Kerkhoff VV; de Oliveira Maciel SFV; de Resende E Silva DT
Purinergic Signal; 2021 Jun; 17(2):179-200. PubMed ID: 33576905
[TBL] [Abstract][Full Text] [Related]
8. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.
Shevchenko I; Mathes A; Groth C; Karakhanova S; Müller V; Utikal J; Werner J; Bazhin AV; Umansky V
Oncoimmunology; 2020 Apr; 9(1):1744946. PubMed ID: 33457090
[TBL] [Abstract][Full Text] [Related]
9. CD73 Rather Than CD39 Is Mainly Involved in Controlling Purinergic Signaling in Calcified Aortic Valve Disease.
Kudryavtsev I; Serebriakova M; Zhiduleva E; Murtazalieva P; Titov V; Malashicheva A; Shishkova A; Semenova D; Irtyuga O; Isakov D; Mitrofanova L; Moiseeva O; Golovkin A
Front Genet; 2019; 10():604. PubMed ID: 31402927
[TBL] [Abstract][Full Text] [Related]
10. CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer.
Li J; Wang L; Chen X; Li L; Li Y; Ping Y; Huang L; Yue D; Zhang Z; Wang F; Li F; Yang L; Huang J; Yang S; Li H; Zhao X; Dong W; Yan Y; Zhao S; Huang B; Zhang B; Zhang Y
Oncoimmunology; 2017; 6(6):e1320011. PubMed ID: 28680754
[TBL] [Abstract][Full Text] [Related]
11. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
[TBL] [Abstract][Full Text] [Related]
12. Studies of the extracellular ATP-adenosine pathway in human urinary tract epithelial cells.
Mohlin C; Säve S; Nilsson M; Persson K
Pharmacology; 2009; 84(4):196-202. PubMed ID: 19729987
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer.
Ploussard G; Dubosq F; Soliman H; Verine J; Desgrandchamps F; De Thé H; Mongiat-Artus P
Urology; 2010 Aug; 76(2):513.e13-8. PubMed ID: 20605198
[TBL] [Abstract][Full Text] [Related]
14. Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity.
Meyer AV; Klein D; de Leve S; Szymonowicz K; Stuschke M; Robson SC; Jendrossek V; Wirsdörfer F
Front Oncol; 2020; 10():554883. PubMed ID: 33194619
[TBL] [Abstract][Full Text] [Related]
15. The Role of Ectonucleotidases CD39 and CD73 and Adenosine Signaling in Solid Organ Transplantation.
Roberts V; Stagg J; Dwyer KM
Front Immunol; 2014; 5():64. PubMed ID: 24600452
[TBL] [Abstract][Full Text] [Related]
16. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
[TBL] [Abstract][Full Text] [Related]
17. CD39 abrogates platelet-derived factors induced IL-1β expression in the human placenta.
Forstner D; Guettler J; Brugger BA; Lyssy F; Neuper L; Daxboeck C; Cvirn G; Fuchs J; Kraeker K; Frolova A; Valdes DS; Stern C; Hirschmugl B; Fluhr H; Wadsack C; Huppertz B; Nonn O; Herse F; Gauster M
Front Cell Dev Biol; 2023; 11():1183793. PubMed ID: 37325567
[TBL] [Abstract][Full Text] [Related]
18. Caffeine reduces viability, induces apoptosis, inhibits migration and modulates the CD39/CD73 axis in metastatic cutaneous melanoma cells.
Manica D; da Silva GB; de Lima J; Cassol J; Dallagnol P; Narzetti RA; Moreno M; Bagatini MD
Purinergic Signal; 2023 Sep; ():. PubMed ID: 37768408
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
